Skip to main content
. 2022 Jun 17;71(9):1994–2008. doi: 10.2337/db22-0177

Figure 2.

Figure 2

Tregs are a nonredundant mechanism of action for sRAGE treatment. A–F: Flow cytometry quantification of Treg-to-Teff ratios on day 64 (A–C) and day 225 (D–F) in NOD/ShiLt mice (n = 4–13/group). G: In an adoptive transfer model of autoimmune diabetes, splenocytes from diabetic NOD/ShiLt donors were adoptively transferred into NOD/SCID recipients. Recipient mice were treated with vehicle or 25 µg sRAGE twice daily for 14 days and isotype control or anti-folate receptor 4 (FR4) monoclonal antibodies (mAb) at 3, 7, 10, and 14 days. Diabetes incidence (three independent experiments, n = 16 mice/group) (H) and flow cytometry quantification of Treg frequencies (n = 16 mice/group) (I and J). I: Quantification of frequencies. J: Representative dot plots. Column graphs are shown as median (IQR), with analysis with two-tailed Mann-Whitney U test. Diabetes incidence is shown with Kaplan-Meier survival curves and was analyzed with log-rank test. *P < 0.05; **P < 0.01; ***P < 0.001.